In vivo assessment of NuvaRing® placement

被引:24
作者
Barnhart, KT [1 ]
Timbers, K
Pretorius, ES
Lin, K
Shaunik, A
机构
[1] Univ Penn, Med Ctr, Dept Obstet & Gynecol, Penn Fertil Care, Philadelphia, PA 19104 USA
[2] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA
关键词
magnetic resonance imaging; NuvaRing (R); female; contraception;
D O I
10.1016/j.contraception.2005.03.012
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
NuvaRing (R), a combined contraceptive vaginal ring 54 mm in diameter, offers many advantages over oral contraceptives. To better delineate in vivo placement, we performed MRI to confirm its anatomical position. Two healthy users, one nulliparous and one parous, underwent a series of MRI: preinsertion, immediately postinsertion and after ambulation. Three-dimensional imaging of the human vagina demonstrates that in vivo, NuvaRing (R) is located superior to the urogenital diaphragm (UGD), surrounding the cervix. The superior-most aspect of the ring lies behind (posterior) the cervix, at a level superior to the external os. The inferior aspect of the ring also lies in the vaginal canal above the UGD. The entire cervix rests inside the ring. The preambulation image in the nulliparous woman was the only exception. In this case, the upper portion of the ring was at the level of the lower-mid cervix and the lower aspect below the UGD. After ambulation, the ring moved cephalad and surrounded the cervix. In all instances, ambulation resulted in lower aspect of NuvaRing (R) moving away from the introitus. In vivo, NuvaRing (R) is compressed laterally forming a gentle oval in the anterior-posterior direction (5-7 min longer than wide), an effect that is seen more in nulliparous women. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:196 / 199
页数:4
相关论文
共 14 条
[1]  
Barnhart K, 2004, J REPROD MED, V49, P83
[2]   Distribution of topical medication in the human vagina as imaged by magnetic resonance imaging [J].
Barnhart, K ;
Pretorius, ES ;
Stolpen, A ;
Malamud, D .
FERTILITY AND STERILITY, 2001, 76 (01) :189-195
[3]   Women's interest in vaginal microbiocides [J].
Darroch, JE ;
Frost, JJ .
FAMILY PLANNING PERSPECTIVES, 1999, 31 (01) :16-23
[4]   Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring [J].
Dieben, TOM ;
Roumen, FJME ;
Apter, D .
OBSTETRICS AND GYNECOLOGY, 2002, 100 (03) :585-593
[5]   Contraceptive failure rates: New estimates from the 1995 National Survey of Family Growth [J].
Fu, HS ;
Darroch, JE ;
Haas, T ;
Ranjit, N .
FAMILY PLANNING PERSPECTIVES, 1999, 31 (02) :56-63
[6]   Contraceptive vaginal rings [J].
Harwood, B ;
Mishell, DR .
SEMINARS IN REPRODUCTIVE MEDICINE, 2001, 19 (04) :381-390
[7]   Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition [J].
Mulders, TMT ;
Dieben, TOM .
FERTILITY AND STERILITY, 2001, 75 (05) :865-870
[8]   Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse [J].
Pretorius, ES ;
Timbers, K ;
Malamud, D ;
Barnhart, K .
CONTRACEPTION, 2002, 66 (06) :443-451
[9]   Use of MRI to determine the in vivo position of a silicone vaginal barrier contraceptive device [J].
Pretorius, ES ;
Barnhart, K ;
Timbers, K ;
Mauck, C .
CONTRACEPTION, 2002, 65 (05) :343-346
[10]  
Roumen F, 2002, EUR J CONTRACEP REPR, V7, P19